98%
921
2 minutes
20
Mercury exposure is a significant environmental concern due to its toxic effects on the human body, especially on the cardiovascular system. Its accumulation induces oxidative stress, inflammation and endothelial dysfunction in systemic arteries, contributing to the development of cardiovascular diseases. The close relationship between systemic and pulmonary circulation leads us to believe that it must also suffer by the toxic effects of HgCl. However, the consequences of HgCl on pulmonary arteries remain unclear. This study aimed to investigate the effects of mercury chloride (HgCl₂) exposure for 60 d on the small intrapulmonary arteries and hemodynamic parameters of male rats. The rats were exposed to HgCl₂ (1st dose, 4.6 μg/kg; subsequent daily doses, 0.07 μg/kg; intramuscular injection). The results revealed that intrapulmonary arteries from exposed rats exhibited reduced contractile responses to potassium chloride and the thromboxane A2 receptor agonist U46619, along with thinning of the arterial wall, which is indicative of vascular remodeling. Impaired pulmonary vasoconstriction in the HgCl group was associated with increased nitric oxide (NO) production and elevated hydrogen peroxide (H₂O₂) levels. In addition, increased production of superoxide anion (O) and reduced superoxide dismutase (SOD) expression were observed and indicates an environment of oxidative stress. Furthermore, HgCl increased systemic blood pressure in conscious animals but reduced left ventricular systolic pressure in anesthetized animals. These findings suggest that chronic HgCl exposure induces pulmonary vascular dysfunctions, primarily through enhanced NO and ROS signaling as an adaptive mechanism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12012-025-10047-x | DOI Listing |
Exp Physiol
September 2025
Department of Physiology, Anatomy & Genetics, University of Oxford, Oxford, UK.
Following acute COVID-19 infection, unvaccinated patients have been reported to exhibit elevated alveolar deadspace (̇V/̇V) and intrapulmonary shunt (̇Q/̇Q) fractions. However, as there is uncertainty surrounding the upper limits of normal for ̇V/̇V and ̇Q/̇Q, we sought to replicate the findings from a separate, previously reported cohort of COVID-19 patients that also included a healthy control group never infected with COVID-19. Data from 81 participants, classified into four different groups based on the severity of prior COVID-19 infection, were used.
View Article and Find Full Text PDFActa Biomater
August 2025
Department of Pharmaceutics and Pharmacy Administration, School of Pharmacy, Air Force Medical University, Xi'an 710032, Shaanxi, China. Electronic address:
Pulmonary hypertension (PH), a condition triggered by various pathogenic factors, is characterized by a progressive increase in intra-pulmonary artery pressure and pulmonary resistance and progressive right ventricular hypertrophy, eventually culminating in right heart failure. Despite the fact that the conventional treatments can alleviate symptoms, they are limited by sub-optimal drug accumulation in the pulmonary vasculature and low bioavailability. Currently, as an emerging technology, the Nano Drug Delivery System (NDDS) has played a decisive role in enhancing drug targeting and precision and concomitantly minimizing side effects.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Laboratory for Cardiovascular Regenerative Medicine, Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Hanzeplein 1 (EA11), 9713 GZ Groningen, The Netherlands.
Pulmonary arterial hypertension (PAH) is a rare, progressive, and incurable disease characterized by an elevated pulmonary blood pressure, extensive remodeling of the pulmonary vasculature, increased pulmonary vascular resistance, and culminating in right ventricular failure. Mitochondrial dysfunction has a major role in the pathogenesis of PAH and secondary right ventricular failure, and its targeting may offer therapeutic benefit. In this study, we provide proof-of-concept for the use of the mitochondrially active drug SUL-150 to treat PAH.
View Article and Find Full Text PDFCardiovasc Toxicol
August 2025
Departamento de Ciências Fisiológicas, Centro de Ciências da Saúde, Universidade Federal do Espírito Santo, Av. Marechal Campos, 1468, Vitória, ES, 29040-091, Brazil.
Mercury exposure is a significant environmental concern due to its toxic effects on the human body, especially on the cardiovascular system. Its accumulation induces oxidative stress, inflammation and endothelial dysfunction in systemic arteries, contributing to the development of cardiovascular diseases. The close relationship between systemic and pulmonary circulation leads us to believe that it must also suffer by the toxic effects of HgCl.
View Article and Find Full Text PDFInt J Cardiovasc Imaging
September 2025
Department of Radiology, Royal Papworth Hospital, Cambridge, UK.
Unilateral atresia of the pulmonary artery (UAPA) is a rare condition often associated with congenital cardiac anomalies, such as tetralogy of Fallot or septal defects. UAPA is linked to an altered development of the sixth aortic arch segment, resulting in the proximal interruption of the pulmonary artery and it often occurs on the side of the chest opposite the aortic arch [1]. As a compensatory mechanism, major aortopulmonary collateral arteries (MAPCAs) arise from systemic arteries to supply distal intrapulmonary branches of the atretic pulmonary artery.
View Article and Find Full Text PDF